Are There Any Emerging DNA Methylation Inhibitors?
Research is ongoing to develop more selective and potent DNA methylation inhibitors. Novel agents such as guadecitabine (SGI-110) and CC-486 (oral azacitidine) are currently under clinical investigation. These emerging inhibitors aim to offer improved pharmacokinetic properties, reduced toxicity, and enhanced efficacy. Additionally, combination therapies involving DNA methylation inhibitors and other epigenetic modulators, such as histone deacetylase inhibitors, are being explored to overcome resistance and achieve synergistic effects.
